Mike Doustdar, new CEO of Ozempic maker, Novo Nordisk discusses his strategy for the future of the company. Walmart employee ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

“Lifestyle changes are associated with modest improvements in sperm motility and morphology, even though the amount of weight ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

The Rise Of GLP-1 Drugs In just three years, drugs like Ozempic have reshaped how society views the body. They reignited a ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...

Novo Nordisk said the overhaul resulted in one-off costs of about DKK 9 billion in 2025, including DKK 5 billion in severance ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

Investing.com -- Novo Nordisk (CSE:NOVOb) on Wednesday said it will cut about 9,000 jobs worldwide, including 5,000 in ...

In today’s news, former WiseTech directors deny they are ASIC targets, Donald Trump attacks New York City voters as mayoral polls close, and UBS’ chairman says markets are echoing the GFC.

A saggy, older, deflated appearance is characteristic of the emaciation now known in Hollywood as “Ozempic face,” named after the prescription weight-loss drug that’s overprescribed in Los Angeles.